{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:08:34Z","timestamp":1784092114148,"version":"3.55.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"BeOne Medicines Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2696131","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:57:21Z","timestamp":1784091441000},"page":"1923-1932","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An unanchored matching-adjusted indirect comparison of the efficacy\u00a0of zanubrutinib versus ibrutinib for the treatment of relapsed\/refractory mantle-cell lymphoma"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[{"name":"Oxford Cancer and Haematology Centre, Churchill Hospital","place":["Oxford, Headington, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["Schiphol, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-2392","authenticated-orcid":false,"given":"Lianne","family":"Barnieh","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0537-978X","authenticated-orcid":false,"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"He","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013326"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"e_1_3_6_9_1","unstructured":"NICE. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma. Guidance TA1081 [Internet]; 2025 [cited 2025 Sept 9]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1081"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024667"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_6_13_1","unstructured":"NICE. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]: committee papers [Internet]. 2025 [cited 2025 Nov 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1081\/documents\/committee-papers"},{"key":"e_1_3_6_14_1","unstructured":"Phillippo D Ades T Dias S et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE [Internet]; 2016 [cited 2025 Oct 2]. Available from: https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/population-adjusted"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2541911"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2025.101088"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01603-3"},{"issue":"2","key":"e_1_3_6_19_1","first-page":"362","article-title":"Zanubrutinib (zanub) in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a Phase 2 study","volume":"5","author":"Song Y","year":"2021","unstructured":"Song Y, Zhou K, Zou D, et al. Zanubrutinib (zanub) in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a Phase 2 study. abst EP789. HemaSphere. 2021;5(S2):362.","journal-title":"HemaSphere"},{"key":"e_1_3_6_20_1","unstructured":"NICE. Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753]; committee papers [Internet]; 2016 [cited 2026 Apr 6]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers"},{"key":"e_1_3_6_21_1","unstructured":"ClinicalTrials.gov. NCT01599949. A study to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy [Internet]; [cited 2026 Apr 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01599949"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.469.469"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2696131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2696131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2696131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:57:22Z","timestamp":1784091442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2696131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2696131"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2696131","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}